Cognoa, a digital health company focused on behavioral health for children, today announced FDA Breakthrough designations for it's first diagnostic and therapeutic devices to identify and treat autism. This is the foundation for its AI-based digital precision health to support the developmental and behavioral health of children, combining diagnostics and therapeutics into one platform. This signifies a big step in the company’s expansion into therapeutics.FDA Breakthrough Devices Program
Read More
Cognoa Lands $11.6M for Machine Learning App to Advance Diagnosis of Autism
Cognoa, a Palo Alto, CA-based digital health startup has raised $11.6 million in funding led by existing investor Morningside to advance earlier diagnosis of development delays in children. The company plans to utilize the funding to advance Cognoa's machine-learning-based technology; support additional clinical validation and the U.S. Food and Drug Administration (FDA) submissions and approvals process; and expand commercialization with employers, payers and clinicians. Cognoa has raised a
Read More